Manuscript Title: Consecutive severe immune-related adverse events after PD-1 inhibitor induction and surgery in

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

Date:____Aug. 6th, 2021____ Your Name: Hang Zhao

Locally Advanced non-small cell lung cancer: A Case Report

| | to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. | | | | | | |
|----------|--|--|---|--|--|--|--|
| | The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u> . | | | | | | |
| to me | the epidemiology of hyperto dication, even if that medic | ension, you should declare ation is not mentioned in t | defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items, | | | | |
| | e time frame for disclosure i | | a in this manuscript without time innit. For an other items, | | | | |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | | | | |
| | | Time frame: Since the initia | l planning of the work | | | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | | | | | |
| | | | | | | | |
| 2 | Grants or contracts from | Time frame: pastXNone | 36 months | | | | |
| | any entity (if not indicated in item #1 above). | | | | | | |
| 3 | Royalties or licenses | XNone | | | | | |
| 4 | Consulting fees | XNone | | | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | XNone | |
|-----|--|--------------------------------|-------------|
| 6 | Payment for expert testimony | XNone | |
| 7 | Support for attending meetings and/or travel | XNone | |
| 8 | Patents planned, issued or pending | XNone | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | XNone | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone | |
| 11 | Stock or stock options | XNone | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X_None | |
| 13 | Other financial or non- financial interests | XNone | |
| Ple | ease summarize the above controls. | onflict of interest in the fol | lowing box: |

Manuscript Title: Consecutive severe immune-related adverse events after PD-1 inhibitor induction and surgery in

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

Date:____Aug. 6th, 2021_ Your Name: Junwei Ning

Locally Advanced non-small cell lung cancer: A Case Report

| Th | | | | |
|----------|--|--|--|----|
| | e following questions apply anuscript only. | to the author's relationshi | ps/activities/interests as they relate to the <u>current</u> | |
| to me | the epidemiology of hypertedication, even if that medic | ension, you should declare ation is not mentioned in pport for the work reporte | defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript. In this manuscript without time limit. For all other iter | ⁄e |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | |
| | | Time frame: Since the initia | l planning of the work | |
| 1 | All support for the present | X None | | |
| 1 | manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | | |
| 1 | manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | Time frame: past | 36 months | |
| 2 | manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | | 36 months | |
| | manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated | Time frame: past | 36 months | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | XNone | |
|-----|--|--------------------------------|-------------|
| 6 | Payment for expert testimony | XNone | |
| 7 | Support for attending meetings and/or travel | XNone | |
| 8 | Patents planned, issued or pending | XNone | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | XNone | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone | |
| 11 | Stock or stock options | XNone | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X_None | |
| 13 | Other financial or non- financial interests | XNone | |
| Ple | ease summarize the above controls. | onflict of interest in the fol | lowing box: |

Manuscript Title: Consecutive severe immune-related adverse events after PD-1 inhibitor induction and surgery in

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a

Date:____Aug. 6th, 2021____

Locally Advanced non-small cell lung cancer: A Case Report

relationship/activity/interest, it is preferable that you do so.

Manuscript number (if known): TLCR-21-603

Your Name: Yu Gu

| The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u> . | | | | | |
|---|---|--|---|--|--|
| The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. | | | | | |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | | |
| | | Time frame: Since the initial | planning of the work | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | | | |
| | | Time frame: past | 36 months | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | | | |
| 3 | Royalties or licenses | XNone | | | |
| 4 | Consulting fees | X_None | | | |
| | | | | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | XNone | |
|-----|--|--------------------------------|-------------|
| 6 | Payment for expert testimony | XNone | |
| 7 | Support for attending meetings and/or travel | XNone | |
| 8 | Patents planned, issued or pending | XNone | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | XNone | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone | |
| 11 | Stock or stock options | XNone | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X_None | |
| 13 | Other financial or non- financial interests | X_None | |
| Ple | ease summarize the above c | onflict of interest in the fol | lowing box: |

Manuscript Title: Consecutive severe immune-related adverse events after PD-1 inhibitor induction and surgery in

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third

Date:____Aug. 6th, 2021____ Your Name: Xiaocheng Zhang

Locally Advanced non-small cell lung cancer: A Case Report

| to | | necessarily indicate a bias | of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so. | : |
|----|---|--|---|------|
| | e following questions apply nuscript only. | to the author's relationsh | ips/activities/interests as they relate to the <u>current</u> | |
| to | | ension, you should declare | defined broadly. For example, if your manuscript pertal all relationships with manufacturers of antihypertensithe manuscript. | |
| | item #1 below, report all su e time frame for disclosure i | | ed in this manuscript without time limit. For all other it | ems, |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | |
| | | Time frame: Since the initia | al planning of the work | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | | |
| | | Time frame: pas | t 36 months | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | | |
| 3 | Royalties or licenses | XNone | | |
| 4 | Consulting fees | XNone | | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | XNone | |
|-----|--|--------------------------------|-------------|
| 6 | Payment for expert testimony | XNone | |
| 7 | Support for attending meetings and/or travel | XNone | |
| 8 | Patents planned, issued or pending | XNone | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | XNone | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone | |
| 11 | Stock or stock options | XNone | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X_None | |
| 13 | Other financial or non- financial interests | X_None | |
| Ple | ease summarize the above c | onflict of interest in the fol | lowing box: |

Manuscript Title: Consecutive severe immune-related adverse events after PD-1 inhibitor induction and surgery in

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a

Date:____Aug. 6th, 2021____

Locally Advanced non-small cell lung cancer: A Case Report

Manuscript number (if known): TLCR-21-603

Your Name: Wen Yu

| rei | ationship/activity/interest, | it is preferable that you do |) SO. |
|-----|---|--|--|
| | e following questions apply nuscript only. | to the author's relationshi | ps/activities/interests as they relate to the <u>current</u> |
| to | | ension, you should declare | defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. |
| | item #1 below, report all sup e time frame for disclosure is | | d in this manuscript without time limit. For all other items, |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | XNone | |
| 3 | Royalties or licenses | XNone | |
| 4 | Consulting fees | XNone | |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | XNone | |
|-----|--|--------------------------------|-------------|
| 6 | Payment for expert testimony | XNone | |
| 7 | Support for attending meetings and/or travel | XNone | |
| 8 | Patents planned, issued or pending | XNone | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | XNone | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone | |
| 11 | Stock or stock options | XNone | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X_None | |
| 13 | Other financial or non- financial interests | XNone | |
| Ple | ease summarize the above controls. | onflict of interest in the fol | lowing box: |

Manuscript Title: Consecutive severe immune-related adverse events after PD-1 inhibitor induction and surgery in

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

Date:____Aug. 6th, 2021____ Your Name: Tianxiang Chen

Locally Advanced non-small cell lung cancer: A Case Report

| rel | ationship/activity/interest, | • | so. |
|----------|--|--|---|
| | e following questions apply nuscript only. | to the author's relationshi | ps/activities/interests as they relate to the <u>current</u> |
| to me | the epidemiology of hypertodication, even if that medic | ension, you should declare ation is not mentioned in t pport for the work reporte | defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other item |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| | | Time frame: Since the initia | planning of the work |
| | All account from the conservation | V None | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | XNone | |
| | manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | Time frame: past | 36 months |
| 2 | manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) | | 36 months |
| | manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated | Time frame: past | 36 months |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | XNone | |
|-----|--|--------------------------------|-------------|
| 6 | Payment for expert testimony | XNone | |
| 7 | Support for attending meetings and/or travel | XNone | |
| 8 | Patents planned, issued or pending | XNone | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | XNone | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone | |
| 11 | Stock or stock options | XNone | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X_None | |
| 13 | Other financial or non- financial interests | XNone | |
| Ple | ease summarize the above controls. | onflict of interest in the fol | lowing box: |

Manuscript Title: Consecutive severe immune-related adverse events after PD-1 inhibitor induction and surgery in

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment

Date:____Aug. 6th, 2021____ Your Name: Qingquan Luo

Locally Advanced non-small cell lung cancer: A Case Report

| | ationship/activity/interest, | • | If you are in doubt about whether to list a so. |
|----|---|--|---|
| | e following questions apply anuscript only. | to the author's relationshi | ps/activities/interests as they relate to the <u>current</u> |
| to | • • | ension, you should declare | defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript. |
| | item #1 below, report all su e time frame for disclosure i | · · · | d in this manuscript without time limit. For all other iter |
| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
| | | Time frame: Since the initia | planning of the work |
| 1 | All support for the present | XNone | |
| 1 | manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | |
| 1 | provision of study materials, medical writing, article processing charges, etc.) | | |
| 1 | provision of study materials, medical writing, article processing charges, etc.) | Time frame: next | 26 months |
| 2 | provision of study materials, medical writing, article processing charges, etc.) | Time frame: pastXNone | 36 months |
| | provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated | _ | 36 months |

| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | XNone | | | |
|-----|--|--------|--|--|--|
| 6 | Payment for expert testimony | XNone | | | |
| 7 | Support for attending meetings and/or travel | XNone | | | |
| 8 | Patents planned, issued or pending | XNone | | | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | XNone | | | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | XNone | | | |
| 11 | Stock or stock options | XNone | | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | X_None | | | |
| 13 | Other financial or non- financial interests | XNone | | | |
| Ple | Please summarize the above conflict of interest in the following box: None. | | | | |